<DOC DOCNO="nw/xinhua/00/chtb_0064@0064@xinhua@nw@en@on">
<ENAMEX TYPE="PERSON">Huiliang Bai</ENAMEX> , director of <ENAMEX TYPE="ORG">the National Pharmaceutical Management Bureau Office</ENAMEX> says that the areas of pharmaceutical industry in which <ENAMEX TYPE="GPE">China</ENAMEX> encourages foreign businesses to invest are : those that can meet the needs of domestic and foreign markets , upgrade product levels , expand foreign sales , increase exports and foreign currency earnings ; enterprises that can produce medicine that can not be produced by <ENAMEX TYPE="GPE">China</ENAMEX> but is urgently needed ; those that can introduce domestically needed advanced technology to reform old enterprises ; those that can introduce new high level technology , patent technology and products ; and those that bring advanced management experience .
He says that apart from investment , the <ENAMEX TYPE="NORP">Chinese</ENAMEX> government also welcomes cooperation of foreign pharmaceutical enterprises to cooperate with <ENAMEX TYPE="GPE">China</ENAMEX> in other ways , such as compensation trade , licensing trade , <ENAMEX TYPE="ORDINAL">third</ENAMEX> party processing , technology transfer , and joint development of new products .
-LRB- End -RRB-
</DOC>
